SynCardia Selected as Finalist
for 2011 World Technology Award
Award Recognizing Visionary Contribution to Science and Technology
to be Presented Oct. 26 in Association with TIME, Fortune and CNN at United Nations
TUCSON, Ariz. – Sept. 14, 2011 – SynCardia Systems, Inc., manufacturer of the world's only FDA, Health Canada and CE approved Total Artificial Heart, announced today that it has been selected as a finalist for the 2011 World Technology Award for Health & Medicine. The award, which honors those doing "innovative work of the greatest likely long-term significance" in science, technology and related fields, is presented by the World Technology Network (WTN) in association with TIME, Fortune, CNN, Science/AAAS and Technology Review.
"Through the peer-nomination and peer-review process, we uncover the best of the best of the best in science and technology," says James P. Clark, Founder and Chairman of WTN. "We discover whose work is going to have the greatest likely impact over time. The World Technology Awards give a snapshot of the amazing science and technology revolutions in process."
SynCardia is currently conducting an FDA-approved Investigational Device Exemption (IDE) clinical study of its Freedom® portable driver, the first wearable power supply for the SynCardia temporary Total Artificial Heart. For the first time in U.S. history, stable patients who meet study criteria are leaving the hospital without human hearts to wait for a matching donor heart at home. Prior to the development of the Freedom driver, U.S. Total Artificial Heart patients were confined to the hospital for months, sometimes years while they waited for a transplant because the only FDA-approved driver, "Big Blue," is hospital-based and weighs 418 pounds.
The other 5 finalists in the Health & Medicine category include:
- Bio-Path Holdings – developed drug delivery technology that provides systemic distribution of nucleic acid drugs through simple intravenous transfusion
- Institute of Microelectronics, Singapore – developed a real-time multifunctional integrated electrocardiogram (ECG) signal processing scheme
- NeuroPace – developed technology designed to decrease or eliminate epilepsy episodes through an implant which monitors the patient's brain, and delivers electric signals to prevent seizures by disrupting any abnormal activity
- Second Sight Medical Products – created a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations
- SpectraScience – developed a technology platform to instantly determine if tissue is normal, pre-cancer or cancerous, without the need for exploratory biopsy.
The winners of the World Technology Awards will be announced during a ceremony at the United Nations on October 26, at the close of the two-day World Technology Summit.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). More than 400 SynCardia Total Artificial Heart implants have been performed since January 2011. The SynCardia Heart has provided almost 130,000 patient days of support from nearly 1,300 implants. The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.